Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: RJMC who wrote (2986)	4/6/2000 11:07:00 AM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

You're right, they really should at least put it on the website. I have a feeling that they're placing the emphasis on Prostate Cancer, which is really the news. I'd guess they're trying to work out the final details of a partnership that establishes ImmunoGen's rights to use the MAB before the scheduled presentation. They may also be in critical negotiations on other partnerships. As you know, I think Mitch is doing a great job, and generally is taking the right direction. Sometimes I think he takes on too much himself, and in so doing he cannot give his complete attention to everything. The conferences this week may have been an example of that. Certainly new partnerships and drugs are more important, however, if someone else had been designated to update the website and prepare P.R. if appropriate, it could have been done as well. It appears to me that C242-DM1 worked so well on its own that results in conjunction with other drugs won't be of major concern, but it would be nice to see the results anyway. Gary